Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MBRX with free AI briefings, catalyst countdowns, and dilution alerts.

MBRX · Moleculin Biotech, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 2.8 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Aug 21, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$7.3M Cash on Hand
2.8mo Cash Runway
Follow MBRX by email Get an email when MBRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MBRX, unsubscribe in one click. Privacy

📣 What MBRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Liposomal Annamycin Leukemia, Myeloid, Acute Phase 1/2 · NCT05319587 Completed
MOL4239 Psoriasis Phase 2 · NCT01826201 Completed
STAT3 Inhibitor WP1066 Glioblastoma, IDH-Wildtype Phase 2 · NCT05879250 Recruiting
WP1122 Healthy Volunteer Phase 1 · NCT05195723 Completed
WP1220 Cutaneous T-Cell Lymphoma/Mycosis Fungoides Phase 1 · NCT04702503 Completed

Also used in these trials (approved or third-party drugs, not MBRX's own candidates): Cytarabine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MBRX holds $7.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.8M/quarter from operations, an estimated runway of 2.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBRX files for a raise →

👥 Who Owns MBRX

Insiders 6.1% Other 5%+ holders 93.9% Institutions (21 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
CVI Investments, Inc. 5%+ holder (13G) 2,161,749 203.64% 2026-09-30
Walter V Klemp
CEO and President, Director · +14.35M options
Insider 36,203 3.41% 2026-11-04
Jonathan P. Foster
Chief Financial Officer · +7.42M options
Insider 20,291 1.91% 2026-11-04
Donald H Picker
Chief Science Officer · +1.79M options
Insider 8,718 0.82% 2026-11-04

Share count 1,061,533 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MBRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.